Antibiotic resistance of Campylobacter species in a pediatric cohort study

Kosek, M.N.; Burga, R.; Colston, J.M.; Schiaffino Salazar, Francesca; François, R.; Pisanic, N.; Peñataro-Yori, P.; Paredes-Olortegui, M.

dc.contributor.author	Schiaffino Salazar, Francesca
dc.contributor.author	Colston, J.M.
dc.contributor.author	Paredes-Olortegui, M.
dc.contributor.author	François, R.
dc.contributor.author	Pisanic, N.
dc.contributor.author	Burga, R.
dc.contributor.author	Peñataro-Yori, P.
dc.contributor.author	Kosek, M.N.
dc.date.accessioned	2019-07-04T16:59:19Z
dc.date.available	2019-07-04T16:59:19Z
dc.date.issued	2019
dc.identifier.uri	https://hdl.handle.net/20.500.12866/6720
dc.description.abstract	The objective of this study was to determine the phenotypic patterns of antibiotic resistance and the epidemiology of drug-resistant Campylobacter spp. from a low-resource setting. A birth cohort of 303 patients was followed until 5 years of age. Stool samples from asymptomatic children (n = 10,008) and those with diarrhea (n = 3,175) were cultured for Campylobacter Disk diffusion for ciprofloxacin (CIP), nalidixic acid (NAL), erythromycin (ERY), azithromycin (AZM), tetracycline (TE), gentamicin (GM), ampicillin (AMP), amoxicillin and clavulanic acid (AMC), ceftriaxone (CRO), chloramphenicol (C), and trimethoprim-sulfamethoxazole (TMS) was determined. Antibiotic resistances in Campylobacter jejuni and non-C. jejuni isolates from surveillance and diarrhea samples were compared, and the association between personal macrolide exposure and subsequent occurrence of a macrolide-resistant Campylobacter spp. was assessed. Of 917 Campylobacter isolates, 77.4% of C. jejuni isolates and 79.8% of non-C. jejuni isolates were resistant to ciprofloxacin, while 4.9% of C. jejuni isolates and 24.8% of non-C. jejuni isolates were not susceptible to azithromycin. Of the 303 children, 33.1% had been diagnosed with a Campylobacter strain nonsusceptible to both azithromycin and ciprofloxacin. Personal macrolide exposure did not affect the risk of macrolide-resistant Campylobacter Amoxicillin and clavulanic acid (94.0%) was one of the antibiotics with the highest rates of susceptibility. There is a high incidence of quinolone- and macrolide-resistant Campylobacter infections in infants under 24 months of age. Given the lack of association between personal exposure to macrolides and a subsequent Campylobacter infection resistant to macrolides, there is a need to evaluate the source of multidrug-resistant (MDR) Campylobacter This study provides compelling evidence to propose amoxicillin/clavulanic acid as a treatment for campylobacteriosis.	en_US
dc.language.iso	eng
dc.publisher	American Society for Microbiology
dc.relation.ispartofseries	Antimicrobial Agents and Chemotherapy
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject	amoxicillin plus clavulanic acid	en_US
dc.subject	ampicillin	en_US
dc.subject	antibiotic agent	en_US
dc.subject	antibiotic resistance	en_US
dc.subject	Antibiotic resistance	en_US
dc.subject	Article	en_US
dc.subject	azithromycin	en_US
dc.subject	Campylobacter	en_US
dc.subject	ceftriaxone	en_US
dc.subject	chloramphenicol	en_US
dc.subject	ciprofloxacin	en_US
dc.subject	clavulanic acid	en_US
dc.subject	cotrimoxazole	en_US
dc.subject	Diarrhea	en_US
dc.subject	erythromycin	en_US
dc.subject	gentamicin	en_US
dc.subject	Iquitos	en_US
dc.subject	macrolide	en_US
dc.subject	MAL-ED	en_US
dc.subject	nalidixic acid	en_US
dc.subject	priority journal	en_US
dc.subject	quinolone	en_US
dc.subject	tetracycline	en_US
dc.title	Antibiotic resistance of Campylobacter species in a pediatric cohort study	en_US
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	https://doi.org/10.1128/AAC.01911-18
dc.subject.ocde	https://purl.org/pe-repo/ocde/ford#3.03.08
dc.subject.ocde	https://purl.org/pe-repo/ocde/ford#3.01.05
dc.relation.issn	1098-6596